How Does Johnson & Johnson’s Revenue And Other Key Metrics Compare With That of Roche?

by Trefis Team
+10.60%
Upside
146
Market
161
Trefis
JNJ
Johnson & Johnson
Rate   |   votes   |   Share

Johnson & Johnson (NYSE:JNJ) and Roche (OTCMKTS: RHHBY) are both primarily engaged in the pharmaceutical business. Johnson & Johnson generated $82 billion in sales in 2018, while Roche garnered $61 billion. For both companies, revenue over the past few years has been impacted by their oncology portfolios. While Johnson & Johnson’s Imbruvica and Darzalex are boosting the company’s top line growth, Roche’s relatively new drugs, including Perjeta, Kadcyla, and Tecentriq are aiding the sales growth. Roche’s cancer drugs portfolio is much bigger than Johnson & Johnson’s. Also, both the companies generate over 40% of their revenues from the U.S. When it comes to profitability, both the companies have posted similar adjusted net income margins in the recent years, with Johnson & Johnson’s slightly better than Roche’s. In this note we compare both the companies’ revenues and other key metrics. You can look at our interactive dashboard analysis ~ Johnson & Johnson vs Roche: How Have Revenues & Other Key Metrics Changed Over Recent Years? ~ for more details.

Johnson & Johnson’s Revenues of $82 Billion Are Much Higher Than $61 Billion For Roche

  • Johnson & Johnson and Roche are both engaged primarily in the pharmaceuticals business.
  • Johnson & Johnson’s revenues have grown from $70.1 billion in 2015 to $81.6 billion in 2018, led by its oncology drugs.
  • Look at our interactive dashboard analysis for more details on Johnson & Johnson’s revenues.
  • Roche’s revenues grew from $52.5 billion in 2015 to $60.7 billion in 2018. Look at our analysis on Roche’s revenues for more details.

Johnson & Johnson And Roche Both Saw Revenue Growth In Mid-Single-Digits

  • Johnson & Johnson’s revenue grew at a CAGR of 5.2% between 2015 and 2018, while the figure was 5.0% for Roche over the same period.
  • Roche’s revenue growth in 2018 was driven by higher sales of its new drug Ocrevus.

US Accounts For Over 40% of The Total Sales For Both The Companies

  • US accounted for 52% of total sales for JNJ in 2018, as compared to 47% in 2015.
  • For Roche, the figure stood at 43% in 2018, as compared to 38% in 2016.

Roche’s Cancer Drugs Portfolio Is Much Larger Than That of Johnson & Johnson

  • Johnson & Johnson’s cancer drugs portfolio saw sales grow from $4.7 billion in 2015 to 9.8 billion in 2018.
  • Roche’s cancer drugs portfolio saw sales grow from $26.0 billion in 2016 to $28.3 billion in 2018.
  • Look at our dashboard analysis on Johnson & Johnson and Roche’s oncology drugs for more details.

Gross Profit Margin For Johnson & Johnson Is Lower Than That of Roche

Johnson & Johnson’s Adjusted Net Income Margin Is Slightly Higher Than That of Roche

  • Johnson & Johnson’s adjusted net income margin grew from 25% in 2015 to 27% in 2018.
  • Roche’s adjusted net income margin grew from 23% in 2015 to 26% in 2018.
  • Look at our interactive dashboard analysis on Johnson & Johnson’s expenses and on Roche’s expenses for more details on how do these companies spend their money.

What’s behind Trefis? See How it’s Powering New Collaboration and What-Ifs

For CFOs and Finance Teams | Product, R&D, and Marketing Teams

More Trefis Data

Like our charts? Explore example interactive dashboards and create your own.

Rate   |   votes   |   Share

Comments

Name (Required)
Email (Required, but never displayed)
Be the first to comment!